Standard titration protocol from clinical trials The Phase 2 NEJM trial used the following escalation schedule for the 12 mg dose group: Weeks 1 through 4: 2 mg once weekly (subcutaneous) Weeks 5 through 8: 4 mg once weekly Weeks 9 through 12: 8 mg once weekly Week 13 and beyond: 12 mg once weekly (maintenance dose) For the 8 mg target dose, the schedule was: Weeks 1 through 4: 2 mg once weekly Weeks 5 through 8: 4 mg once weekly Week 9 and beyond: 8 mg once weekly (maintenance dose) These titration schedules are not suggestions
Regenerative peptides have gained a lot of attention in sports medicine, rehab, and the broader biohacking world
Despite the hype, liposomal and intravenous NAD+ products also fall short, as they do not reliably replenish cellular NAD+ levels
Despite mature production technologies, ensuring batch-to-batch consistency remains difficult
Related LIVV peptides and stacks LIVVs BPC-157 product page if you want to review it with a licensed provider
reuteri exhibits certain antioxidant activity, which helps mitigate oxidative injury in the liver
